← Research library

Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.

Observational study · 1983

What was studied
67 withdrawal patients enrolled; 49 evaluable
Main finding
An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.

Reported findings and study design

An uncontrolled withdrawal report described improvement in 48 of 49 evaluable patients after DSIP, but 18 of 67 enrolled patients were not evaluable.

67 patients with withdrawal symptoms: alcohol 28, opiates 39; DSIP was the sole reported treatment.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Reported beneficial response48/49 evaluable22 alcohol-withdrawal patients and 26/27 opiate-withdrawal patients
Attrition18/67 not evaluable; abstract reports 27%49 patients contributed to the response analysis
Major adverse effectsNone reportedLimited uncontrolled clinical series
Studied regimen25 nmol/kg intravenously

The evaluable-patient response excludes substantial attrition and has no placebo comparator. It does not establish a safe or effective withdrawal treatment.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • No control group and substantial exclusion/loss prevent causal conclusions. Not a basis for self-treatment of withdrawal.

Source details

Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology 10(4):205-208

Study source ↗ · DOI 10.1159/000118012 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards